Zhen Wang

发表

Design, synthesis and biological evaluation of 3-arylisoquinoline derivatives as topoisomerase I and II dual inhibitors for the therapy of liver cancer.

Yuehua Li, Li-ming Xie, Linyi Liu, 2022, European journal of medicinal chemistry.

Design, synthesis and bioactivity evaluation of novel N-phenyl-substituted evodiamine derivatives as potent anti-tumor agents.

Xiaoyan Yang, Honghua Zhang, X. Hao, 2021, Bioorganic & medicinal chemistry.

The discovery of a new structural class of potent orally active leukotriene D4 antagonists

R. Young, P. Prasit, A. Ford-hutchinson, 1992 .

Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase.

D. Zaller, D. Schmatz, S. O'keefe, 2003, Bioorganic & medicinal chemistry letters.

p38 Inhibitors: piperidine- and 4-aminopiperidine-substituted naphthyridinones, quinolinones, and dihydroquinazolinones.

A. Woods, D. Zaller, S. O'keefe, 2003, Bioorganic & medicinal chemistry letters.

Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors.

Xianglong Zhu, Yajing Liu, Ye Chen, 2020, Bioorganic chemistry.

The unanticipated loss of SO2 from sulfonamides in collision-induced dissociation.

T. Baillie, C. Hop, Mi-Sook Kim, 2003, Rapid communications in mass spectrometry : RCM.

The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs.

A. Robichaud, T. Baillie, R. Anari, 2004, Drug metabolism and disposition: the biological fate of chemicals.

Substituted N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-phenylalanine analogues as potent VLA-4 antagonists.

M. Maccoss, W. Hagmann, K. Lyons, 2002, Bioorganic & medicinal chemistry letters.

Synthesis and Biological Evaluation of 2,3-Diarylthiophenes as Selective COX-2 Inhibitors. Part 2. Replacing the Heterocycle

D. Riendeau, P. Prasit, W. Cromlish, 1996 .